Use of Tinzaparin for Anticoagulation in Hemodialysis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.
Also called NCT01930396
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 191 participants
- Sponsor
- Registry
-
NCT01930396
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT01930396. Randomized; quadruple masking; primary purpose prevention. Start 2013-09 (registry gives no type); primary completion 2016-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of Tinzaparin for Anticoagulation in Hemodialysis
- Acronym
- HEMO-TIN
- Condition
- Kidney Failure, Chronic
- Intervention (Drug)
- Tinzaparin
- Intervention (Drug)
- Unfractionated Heparin
- Intervention (Drug)
- Placebo (for Tinzaparin)
- Intervention (Drug)
- Placebo (for Unfractionated Heparin)
- Lead sponsor
- Christine Ribic
- Collaborator
- McMaster University
- Collaborator
- LEO Pharma
Record details
- Record id
cardio:ct-nct01930396- Content hash
8e5c4b0e45471b9b981832394da570d5da475e830199b9da2928bcb9eca7e4f1